NEWS & MEDIA
CAVHANZA™ is the first FDA-approved orally disintegrating tablet formulation of nilotinib and offers a new treatment option for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
Read Full article
CAVHANZA™ is the first FDA-approved orally disintegrating tablet formulation of nilotinib and offers a new treatment option for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
The approval of CAVHANZA™ follows PHYRAGO®, demonstrating a repeatable path from proprietary particle engineering to differentiated, FDA-approved medicines NEW BRIGHTON,…